During the last session, iBio Inc (AMEX:IBIO)’s traded shares were 0.39 million, with the beta value of the company hitting -3.27. At the end of the trading day, the stock’s price was $3.07, reflecting an intraday gain of 1.99% or $0.06. The 52-week high for the IBIO share is $4.98, that puts it down -62.21 from that peak though still a striking 65.8% gain since the share price plummeted to a 52-week low of $1.05. The company’s market capitalization is $28.09M, and the average intraday trading volume over the past 10 days was 0.34 million shares, and the average trade volume was 132.92K shares over the past three months.
iBio Inc (IBIO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. IBIO has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.45.
iBio Inc (AMEX:IBIO) trade information
iBio Inc (IBIO) registered a 1.99% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.99% in intraday trading to $3.07, hitting a weekly high. The stock’s 5-day price performance is 8.10%, and it has moved by 23.79% in 30 days. Based on these gigs, the overall price performance for the year is 184.26%. The short interest in iBio Inc (AMEX:IBIO) is 0.19 million shares and it means that shorts have 2.47 day(s) to cover.
The consensus price target of analysts on Wall Street is $3.6, which implies an increase of 14.72% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3.6 and $3.6 respectively. As a result, IBIO is trading at a discount of -17.26% off the target high and -17.26% off the low.
iBio Inc (IBIO) estimates and forecasts
Statistics show that iBio Inc has outperformed its competitors in share price, compared to the industry in which it operates. iBio Inc (IBIO) shares have gone up 42.79% during the last six months, with a year-to-date growth rate more than the industry average at 56.82% against 16.50. In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 57.55%. While earnings are projected to return 62.28% in 2025.
IBIO Dividends
iBio Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
iBio Inc (AMEX:IBIO)’s Major holders
iBio Inc insiders own 0.16% of total outstanding shares while institutional holders control 30.89%, with the float percentage being 30.94%.
Also, the Mutual Funds coming in first place with the largest holdings of iBio Inc (IBIO) shares are Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Nov 30, 2024 indicates that Fidelity Extended Market Index Fund owns about 47.16 shares. This amounts to just over 0.52 percent of the company’s overall shares, with a $0.14 million market value. The same data shows that the other fund manager holds slightly less at 36.0, or about 0.39% of the stock, which is worth about $0.11 million.
